ACP 2024 Insights: Acute Coronary Syndromes - Evaluation, Diagnosis …

Insights from 2024 ACP Annual Meeting

D. Berg

Apolipoprotein B & CVD Risk: How Can We Improve CVD Prevention With …

ASPC 2020 Virtual Summit on CVD Prevention

A. Sniderman

The Enigma of Shock: Cutting Edge Approaches to Undifferentiated Sho…

Houston Methodist

H. Mallemat

Management of Women with Complex Medical Conditions: Cardiovascular …

Cynthia Stuenkel

Cardiometabolic Medicine: Does SGLT2i Improve HFrEF Symptoms, QOL, R…

Cardiometabolic Health Congress (CMHC)

K. Ferdinand

How Can We Prevent the Majority of CV Events? What Are the Milion He…

ASPC 2020 Virtual Summit on CVD Prevention

L. Sperling

Polypill for CVD Prevention: When Is Polypharmacy Appropriate? Can R…

ASPC 2020 Virtual Summit on CVD Prevention

K. Ferdinand

Menopause and Its Impact on Women's CVD Health: How to Assess Risk F…

ASPC 2020 Virtual Summit on CVD Prevention

E. Michos

Cardiometabolic Medicine: What Are the Trends in Mortality, Risk & B…

Cardiometabolic Health Congress (CMHC)

K. Ferdinand

Why and Who Needs to See a Preventive Cardiologist?

Houston Methodist DeBakey Heart and Vascular Center

M. Shapiro

Lymphedema: Treatment Options For Severe Lifestyle Limiting Lymphede…

Complex Coronary Valvular and Vascular Cases Conference

CVD Prevention for Women: What Are the Unique/Predominant Risk Facto…

ASPC 2020 Virtual Summit on CVD Prevention

N. Wenger

Vascular medicine for the practicing cardiologist

Innovations in Cardiovascular Therapeutics 2016

T. Polonsky

New Insights Into Assessing Risk for Hispanic Patients: Why it Is Im…

ASPC 2020 Virtual Summit on CVD Prevention

I. Pina

Examining the Case For Just In Case Vascular Access Discussion

AVA at Your Fingertips

J. A. Bell

How to Improve Vascular Access for Patients? What Are The Steps for …

AVA at Your Fingertips

J. A. Bell

Medication Compliance: Motivating Providers and Patients to Do the R…

New Cardiovascular Horizons (NCVH) 2017